Seagen Inc., a biotechnology company, is pioneering the field of targeted therapies to treat cancer. The company focuses on developing and commercializing a new class of therapies called antibody-drug conjugates (ADCs). These novel treatments are designed to target and destroy cancer cells while sparing healthy cells, offering a more precise approach to cancer therapy.
Founded in 1998, Seagen Inc., originally known as Seattle Genetics, is headquartered in Bothell, Washington, United States. The company has established itself as a leader in the ADC technology, making significant strides in cancer treatment.
Seagen's key products include ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), and TIVDAK® (tisotumab vedotin-tftv), all of which are used in various treatments for different types of cancer.
|Mr. David R. Epstein B.Sc., M.B.A.||CEO & Director||1.39M||N/A||1962|
|Mr. Todd E. Simpson||Chief Financial Officer||1.26M||N/A||1961|
|Dr. Vaughn B. Himes Ph.D.||Chief Technical Officer||1.08M||3.16M||1961|
|Ms. Jean I. Liu J.D., M.S.||Chief Legal Officer & Corporate Secretary||1.23M||1.27M||1968|
|Mr. Charles R. Romp||Executive Vice President of Commercial U.S.||1.08M||N/A||1968|
|Dr. Roger D. Dansey M.D.||Chief Medical Officer and President of Research & Development||2.48M||6.2M||1956|
|Mr. William Compton||Senior VP of Global Information Technology & CIO||N/A||N/A||N/A|
|Mr. David Caouette||Vice President of Corporate Communications||N/A||N/A||N/A|
|Mr. Matt Skelton||Vice President of Marketing||N/A||N/A||N/A|
|Ms. Peggy M. Pinkston||Chief Human Resources Officer||N/A||N/A||N/A|